丽珠集团 (000513)

LIVZON PHARMACEUTICAL GROUP INC.

ASZ

Tags

DeepSeekCSI Share Buyback IndexInnovative DrugsChemical PharmaceuticalsContains H-SharesGuoxin Value IndexGuozheng Value IndexGene ConceptSmall Cap ValueSustainable GrowthPrivate Enterprises 100 IndexBiological VaccinesGuangdong-Hong Kong-Macao Greater Bay AreaHigh-Performing StocksFree Cash FlowAssisted ReproductionNorthbound Connect Heavy PositionsShenzhen ConnectSZSE 300 IndexSZSE Value IndexTech 100 IndexCSFC HoldingsPharma & BiotechSZSE Defensive 50 IndexGreater Bay Area IndexSZSE Medicine Equal Weight IndexPharmaceutical IndexShenzhen A-Share Pharmaceutical IndexSHS Dividend Growth Low Volatility IndexCSI All-share Pharmaceutical Sector IndexCSI 800 Dividend Low Volatility IndexSZSE Emerging Industries IndexSZSE 1000 IndexSZSE 300 Return IndexCSSW Health IndexSZSE Component Index ReturnCNI 1000 IndexXingyin Wealth Management Balanced 300 IndexCR Foundation IndexCSSW Silk Road IndexSZSE Performance IndexOrient Securities Value IndexCSI 500 Value Stable IndexShenzhen-Hong Kong Stock ConnectNew Virus PreventionCOVID-19 PreventionAntigen Self-testOptimized Fertility (Three-child)Gene SequencingCOVID-19 TestingFTSE Russell ConceptHuijin ConceptInsurance Heavy HoldingsNEEQPrecision MedicinePublic Health IndexSHS Greater Bay Area IndexSZSE Selected IndexTechnology 50 Strategy IndexCS High-end Manufacturing IndexSZSE Technology IndexSHS Innovative Drugs IndexSZSE ChiNext 100 IndexSecurities Times Value 100 IndexSZSE Pharmaceutical IndexDividend Quality IndexCSI 800 IndexCS Pharmaceutical TI IndexCNI Pharmaceutical IndexCSI 1000 Pharmaceutical IndexJuchao Small-cap IndexCCTV 500 IndexDividend 100 IndexSZSE Component Pharmaceutical IndexPharmaceutical Sub-sector IndexSZSE Low Volatility IndexCSI All-share Pharmaceutical IndexSZSE Pharmaceutical 50 IndexSZSE 300 Equal Weight IndexCSI 500 Equal Weight IndexCSI 800 Pharmaceutical IndexSZSE Component Index Equal WeightCS Biomedicine IndexPharmaceutical & Health 100 IndexInnovative Drugs 30 IndexCSI 700 IndexAH Economic Blue-chip IndexMid-small Cap IndexSZSE Fundamental 200 IndexCSI 500 IndexCSI 500 IndexPharmaceutical 50 IndexSmall-cap Low Volatility IndexCSI 500 Growth Innovation IndexPharmaceutical 50 Strategy IndexSZSE 200 Return IndexSZSE 200 IndexCICC 300 IndexSZSE Dividend 50 IndexCS Innovative Drugs IndexESG 300 IndexCR New Momentum IndexDividend 200 IndexChina Economic Index GDPCSI 1000 Value IndexSZSE 500 IndexFundamental 600 IndexCSI 500 ESG IndexCSI 800 Cash Flow IndexPerformance IndexCSI Cash Flow IndexGuangdong

K-Line Chart

No K-line data available

Company NameLivzon Pharmaceutical Group Inc.
Listing Date1993-10-28
Issue Price6.38RMB
Registered Capital90410.04310k RMB
Legal RepresentativeZhu Baoguo
Registered AddressHeadquarters Building, No. 38 Chuangye North Road, Jinwan District, Zhuhai City, Guangdong Province
IndustryChemical Pharmaceuticals
Main BusinessProduction of pharmaceutical products, including Chinese and Western patent medicines, pharmaceutical APIs (active pharmaceutical ingredients), pharmaceutical intermediates, Chinese medicinal materials, prepared slices of Chinese crude drugs, health supplements, health foods, cosmetics, sanitary materials, sanitary products, biological products, biochemical reagents, medical devices, etc.
Company ProfileLivzon Pharmaceutical Group Inc. was founded in January 1985 with a registered capital of 953 million yuan. It is a comprehensive pharmaceutical group integrating R&D, production, and sales, with over 9,000 employees. In 1993, Livzon's A-shares and B-shares were successively listed. In 2014, the company completed the conversion of B-shares to H-shares, making it one of the few A+H share listed pharmaceutical companies in the capital market. In 2019, the company's total assets were 17.976 billion RMB, annual operating revenue was 9.385 billion RMB, net profit was 1.462 billion RMB, and R&D investment was 827 million RMB. Livzon is committed to ensuring product efficacy, safety, and stability. All group pharmaceutical enterprises have established comprehensive quality management systems. As of 2019: 31 production lines across 4 subsidiary formulation enterprises have passed GMP certification; 28 varieties from 4 API enterprises have passed GMP certification, with an additional 11 varieties passing veterinary drug GMP certification; 15 API varieties have passed on-site international certification inspections, obtaining 20 international certification certificates.

Stock Details

1. Key Indicators

  • Total Shares(W): 90410.04
  • Circulating A-Shares(W): 58414.63
  • Earnings Per Share(RMB): 1.9600
  • Net Assets Per Share(RMB): 15.4439
  • Operating Revenue(W RMB): 911591.43
  • Total Profit(W RMB): 249654.50
  • Net Profit Attributable to Parent(W RMB): 175410.03
  • Net Profit Growth Rate(%): 4.86
  • Weighted Return on Equity(%): 12.4900
  • Operating Cash Flow Per Share(RMB): 2.7930
  • Undistributed Profit Per Share(RMB): 13.8550
  • Capital Reserve Per Share(RMB): 0.3305

2. Main Business

The main business covers:

  • Research, production, and sales of pharmaceutical products

3. Company Basic Information

  • Company Name: Livzon Pharmaceutical Group Inc.
  • Listing Date: 1993-10-28
  • Industry: Pharmaceutical Manufacturing
  • Address: Headquarters Building, No. 38 Chuangye North Road, Jinwan District, Zhuhai City, Guangdong Province
  • Website: www.livzon.com.cn
  • Company Profile: The company's predecessor was Livzon Pharmaceutical (Group) Co., Ltd. It began a shareholding system restructuring in March 1992, converting the original company's net assets into 48.64 million shares for domestic promoters and 15.20 million shares for overseas promoters. After two public offerings in June and September of the following year, the total number of shares reached 162.88 million when the A-shares were listed on October 28, 1993. The 28.346 million employee shares were listed for trading on September 29, 1994.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Joincare Pharmaceutical Group Industry Co., Ltd. General Legal Person 22137.68 37.90
2 Hong Kong Securities Clearing Company Ltd. Northbound Funds 1886.26 3.23
3 Shenzhen Haibin Pharmaceutical Co., Ltd. General Legal Person 1683.08 2.88
4 Guotai Asset Management Co., Ltd. - Social Security Fund 1102 Portfolio Social Security Fund 588.17 1.01
5 CSI 500 Exchange Traded Open-End Index Securities Investment Fund Fund 528.53 0.90
6 China Life Insurance Company Limited - Traditional - General Insurance Product - 005L-CT001 Hu General Legal Person 479.35 0.82
7 China Europe Healthcare Hybrid Securities Investment Fund Class A Fund 362.68 0.62
8 Yinhua CSI Innovative Pharmaceutical Industry Exchange Traded Open-End Index Securities Investment Fund Fund 353.42 0.61
9 Guotai Great Health Equity Securities Investment Fund Class A Fund 48.62 0.08
10 Red Soil Innovation Enhanced Return Bond Securities Investment Fund Class A Fund 42.68 0.07

5. Concept Sectors

  • H-Share
  • Biological Vaccine
  • Gene Concept
  • Guangdong-Hong Kong-Macao Greater Bay Area
  • Assisted Reproduction
  • Innovative Drugs
  • Weight Loss Drugs
  • Pet Economy
  • DeepSeek
  • Margin Trading & Securities Lending
  • High-Performance Stock
  • Sustained Growth
  • Heavily Held by Northbound Funds
  • Free Cash Flow
  • SZSE Value
  • Small Cap Value
  • SZSE 300
  • SZSE Dividend
  • CNI Value
  • Guoxin Value
  • CSI Buyback

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information